Article: Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
2020 Volume 121, Issue 11, Page(s) 817–821
Abstract: ... ventricular arrhythmias in patients treated with hydroxychloroquine and concomitant azithromycin for COVID-19 ... Method: A total of 81 patients who had hydroxychloroquine and azithromycin combination therapy ... Background: Combination of hydroxychloroquine and azithromycin for the treatment of coronavirus ...
| Abstract | Background: Combination of hydroxychloroquine and azithromycin for the treatment of coronavirus disease 2019 (COVID-19) carries increased risk of corrected QT (QTc) prolongation and cardiac arrhythmias. Objective: To characterize the ventricular repolarization indexes which are associated with malignant ventricular arrhythmias in patients treated with hydroxychloroquine and concomitant azithromycin for COVID-19. Method: A total of 81 patients who had hydroxychloroquine and azithromycin combination therapy because of possible or reverse-transcription polymertase chain reaction (RT-PCR) confirmed diagnosis of COVID-19 were included in the study. Baseline and control electrocardiograms (before and after treatment) were analyzed retrospectively. Tp-e interval, Tp-e/QT and Tp-e/QTc ratios, which are ventricular repolarization indexes, were calculated. Results: While there was no significant increase in QTc interval in patients receiving combination therapy, there was a significant increase in ventricular repolarization indexes. Conclusion: The increase in ventricular replarization indexes is associated with the risk of arrhythmia. In patients using QTc prolonging medication for COVID-19 treatment, QTc monitoring alone may not be sufficient to follow-up for arrhythmia. Even if there is no prolongation in QTc, an increase in ventricular repolarization indexes may be seen (Tab. 5, Ref. 37). |
|---|---|
| MeSH term(s) | Azithromycin/adverse effects ; Betacoronavirus ; Coronavirus Infections/drug therapy ; Drug Therapy, Combination ; Electrocardiography ; Humans ; Hydroxychloroquine/adverse effects ; Long QT Syndrome/chemically induced ; Pandemics ; Pneumonia, Viral/drug therapy ; Retrospective Studies |
| Chemical Substances | Hydroxychloroquine (4QWG6N8QKH) ; Azithromycin (83905-01-5) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-11-09 |
| Publishing country | Slovakia |
| Document type | Journal Article |
| ZDB-ID | 127421-1 |
| ISSN | 0006-9248 |
| ISSN | 0006-9248 |
| DOI | 10.4149/BLL_2020_134 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 355: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.